Comprehensive Stock Comparison
Compare Aurinia Pharmaceuticals Inc. (AUPH) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AUPH | 20.4% revenue growth vs CANF's -9.3% |
| Quality / Margins | AUPH | 101.5% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs AUPH's 0.64, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs AUPH's +78.2% |
| Efficiency (ROA) | AUPH | 38.2% ROA vs CANF's -114.0%, ROIC 16.6% vs -448.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for autoimmune diseases with unmet medical needs. It generates revenue primarily from sales of LUPKYNIS — its FDA-approved oral treatment for lupus nephritis — with additional income from its collaboration and licensing agreement with Otsuka Pharmaceutical. The company's key advantage is its first-mover position in the oral treatment space for lupus nephritis, a serious kidney complication of systemic lupus erythematosus where treatment options have been limited.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AUPH leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). CANF leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
AUPH is the larger business by revenue, generating $283M annually — 505.5x CANF's $560,000. AUPH is the more profitable business, keeping 101.5% of every revenue dollar as net income compared to CANF's -15.7%. On growth, AUPH holds the edge at +28.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $283M | $560,000 |
| EBITDAEarnings before interest/tax | $105M | -$9M |
| Net IncomeAfter-tax profit | $287M | -$9M |
| Free Cash FlowCash after capex | $135M | -$8M |
| Gross MarginGross profit ÷ Revenue | +88.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | +37.1% | -16.0% |
| Net MarginNet income ÷ Revenue | +101.5% | -15.7% |
| FCF MarginFCF ÷ Revenue | +47.8% | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.8% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +152.0% | +36.4% |
Valuation Metrics
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $1.9B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | 6.85x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.87x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.82x | — |
| Price / SalesMarket cap ÷ Revenue | 6.62x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 3.38x | 6.34x |
| Price / FCFMarket cap ÷ FCF | 13.85x | — |
Profitability & Efficiency
AUPH delivers a 49.4% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-2 for CANF. CANF carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AUPH's 0.13x. On the Piotroski fundamental quality scale (0–9), AUPH scores 7/9 vs CANF's 1/9, reflecting strong financial health.
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | +49.4% | -2.1% |
| ROA (TTM)Return on assets | +38.2% | -114.0% |
| ROICReturn on invested capital | +16.6% | -4.5% |
| ROCEReturn on capital employed | +18.9% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 1 |
| Debt / EquityFinancial leverage | 0.13x | 0.02x |
| Net DebtTotal debt minus cash | -$5M | -$5M |
| Cash & Equiv.Liquid assets | $80M | $5M |
| Total DebtShort + long-term debt | $75M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in AUPH five years ago would be worth $9,786 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs AUPH's +78.2%. The 3-year compound annual growth rate (CAGR) favors CANF at 20.6% vs AUPH's 15.9% — a key indicator of consistent wealth creation.
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | -7.7% | +2059.1% |
| 1-Year ReturnPast 12 months | +78.2% | +169.9% |
| 3-Year ReturnCumulative with dividends | +55.9% | +75.3% |
| 5-Year ReturnCumulative with dividends | -2.1% | -76.5% |
| 10-Year ReturnCumulative with dividends | +497.9% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +15.9% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than AUPH's 0.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs AUPH's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.64x | 0.36x |
| 52-Week HighHighest price in past year | $16.54 | $4.93 |
| 52-Week LowLowest price in past year | $6.83 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +85.7% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 37.4 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 782K | 4.3M |
Analyst Outlook
Wall Street rates AUPH as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 9.4% for AUPH (target: $16).
| Metric | AUPHAurinia Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.50 | $7.25 |
| # AnalystsCovering analysts | 14 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | 100 | 86.97 | -13.0% |
| Can-Fite BioPharma … (CANF) | 100 | 33.04 | -67.0% |
Aurinia Pharmaceuti… (AUPH) returned -2% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | $173000.00 | $283M | +163515.6% |
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
Aurinia Pharmaceuticals Inc.'s revenue grew from $0M (2016) to $283M (2025) — a 127.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -134.7% | 101.5% | +175.4% |
| Can-Fite BioPharma … (CANF) | -40.7% | -11.7% | +71.3% |
Aurinia Pharmaceuticals Inc.'s net margin went from -135% (2016) to 101% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -0.66 | 2.07 | +413.6% |
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
Aurinia Pharmaceuticals Inc.'s EPS grew from $-0.66 (2016) to $2.07 (2025).
Chart 5Free Cash Flow — 5 Years
Aurinia Pharmaceuticals Inc. generated $135M FCF in 2025 (+185% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
AUPH vs CANF: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AUPH or CANF a better buy right now?
Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 6.8x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AUPH or CANF?
Over the past 5 years, Aurinia Pharmaceuticals Inc. (AUPH) delivered a total return of -2.1%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in AUPH five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AUPH returned +497.9% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AUPH or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Aurinia Pharmaceuticals Inc.'s 0.64β — meaning AUPH is approximately 77% more volatile than CANF relative to the S&P 500. On balance sheet safety, Can-Fite BioPharma Ltd. (CANF) carries a lower debt/equity ratio of 2% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AUPH or CANF?
Aurinia Pharmaceuticals Inc. (AUPH) is the more profitable company, earning 101.5% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps 101.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37.1% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is AUPH or CANF more undervalued right now?
Analyst consensus price targets imply the most upside for CANF: 52.6% to $7.25.
06Which pays a better dividend — AUPH or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AUPH or CANF better for a retirement portfolio?
For long-horizon retirement investors, Aurinia Pharmaceuticals Inc. (AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.64), +497.9% 10Y return). Both have compounded well over 10 years (AUPH: +497.9%, CANF: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AUPH and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: AUPH is a small-cap deep-value stock; CANF is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.